Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $16 | $13 | $12 | $0 |
| % Growth | 17% | 11.1% | – | – |
| Cost of Goods Sold | $1 | $3 | $2 | $1 |
| Gross Profit | $15 | $11 | $11 | -$1 |
| % Margin | 95.1% | 80.1% | 87.3% | – |
| R&D Expenses | $62 | $75 | $64 | $42 |
| G&A Expenses | $0 | $0 | $0 | $21 |
| SG&A Expenses | $24 | $28 | $23 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1 |
| Other Operating Expenses | $0 | -$1 | $0 | -$0 |
| Operating Expenses | $87 | $104 | $88 | $62 |
| Operating Income | -$72 | -$93 | -$77 | -$62 |
| % Margin | -455.1% | -687.8% | -633.7% | – |
| Other Income/Exp. Net | -$3 | -$4 | $43 | -$3 |
| Pre-Tax Income | -$75 | -$97 | -$34 | -$65 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$75 | -$97 | -$34 | -$65 |
| % Margin | -475.3% | -717.7% | -279.3% | – |
| EPS | -50.78 | -69.74 | -29.98 | -69.34 |
| % Growth | 27.2% | -132.6% | 56.8% | – |
| EPS Diluted | -50.78 | -69.74 | -29.98 | -69.34 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $1 |
| Interest Expense | $5 | $4 | $4 | $4 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$69 | -$92 | -$29 | -$62 |
| % Margin | -435.8% | -681.5% | -242.9% | – |